Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 6
1970 2
1973 2
1974 3
1975 2
1976 4
1977 3
1978 3
1979 2
1980 4
1981 3
1982 5
1983 4
1984 7
1985 5
1986 12
1987 7
1988 7
1989 13
1990 12
1991 7
1992 16
1993 12
1994 9
1995 15
1996 12
1997 10
1998 20
1999 11
2000 17
2001 12
2002 10
2003 18
2004 15
2005 15
2006 7
2007 10
2008 13
2009 16
2010 20
2011 17
2012 12
2013 6
2014 4
2015 8
2016 8
2017 7
2018 8
2019 10
2020 11
2021 13
2022 12
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

461 results
Results by year
Filters applied: . Clear all
Page 1
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Wu YL, et al. Among authors: linke r. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25. Lancet Oncol. 2017. PMID: 28958502 Clinical Trial.
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q, Zhou J, Du Y, Yu P, Liu X, Hu C, Lu Y, Zhang Y, Lee KH, Nakagawa K, Linke R, Wong CH, Tang Y, Zhu F, Wilner KD, Wu YL. Cheng Y, et al. Among authors: linke r. Lung Cancer. 2021 Apr;154:176-185. doi: 10.1016/j.lungcan.2021.02.025. Epub 2021 Feb 23. Lung Cancer. 2021. PMID: 33721611 Free article. Clinical Trial.
Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
Lodrini M, Graef J, Thole-Kliesch TM, Astrahantseff K, Sprüssel A, Grimaldi M, Peitz C, Linke RB, Hollander JF, Lankes E, Künkele A, Oevermann L, Schwabe G, Fuchs J, Szymansky A, Schulte JH, Hundsdörfer P, Eckert C, Amthauer H, Eggert A, Deubzer HE. Lodrini M, et al. Among authors: linke rb. Clin Cancer Res. 2022 May 2;28(9):1809-1820. doi: 10.1158/1078-0432.CCR-21-3716. Clin Cancer Res. 2022. PMID: 35247920
The Relevance of G-Quadruplexes for DNA Repair.
Linke R, Limmer M, Juranek SA, Heine A, Paeschke K. Linke R, et al. Int J Mol Sci. 2021 Nov 22;22(22):12599. doi: 10.3390/ijms222212599. Int J Mol Sci. 2021. PMID: 34830478 Free PMC article. Review.
Sexual Crossing of Trichoderma reesei.
Linke RB. Linke RB. Methods Mol Biol. 2021;2234:79-85. doi: 10.1007/978-1-0716-1048-0_7. Methods Mol Biol. 2021. PMID: 33165781
Amyloidogenicity assessment of transthyretin gene variants.
Grether NB, Napravnik F, Imhof T, Linke RP, Bräsen JH, Schmitz J, Dohrn M, Schneider C, Svačina MKR, Stetefeld J, Koch M, Lehmann HC. Grether NB, et al. Among authors: linke rp. Ann Clin Transl Neurol. 2022 Aug;9(8):1252-1263. doi: 10.1002/acn3.51626. Epub 2022 Jul 29. Ann Clin Transl Neurol. 2022. PMID: 35903975 Free PMC article.
AA amyloidosis in inflammatory active malignant paraganglioma.
Ihne S, Kircher M, Papagianni A, Goetze O, Morbach C, Werner RA, Zeller D, Sommer C, Rosenwald A, Amann K, Linke RP, Lapa C, Einsele H, Geier A, Obici L, Palladini G, Knop S, Störk S. Ihne S, et al. Among authors: linke rp. Amyloid. 2022 Jun;29(2):137-138. doi: 10.1080/13506129.2021.2016691. Epub 2022 Feb 2. Amyloid. 2022. PMID: 35107388 No abstract available.
Bullous amyloidosis.
Ruzicka T, Schmoeckel C, Ring J, Linke RP, Braun-Falco O. Ruzicka T, et al. Among authors: linke rp. Br J Dermatol. 1985 Jul;113(1):85-95. doi: 10.1111/j.1365-2133.1985.tb02047.x. Br J Dermatol. 1985. PMID: 3893515
A molecular history of the amyloidoses.
Buxbaum JN, Linke RP. Buxbaum JN, et al. Among authors: linke rp. J Mol Biol. 2012 Aug 10;421(2-3):142-59. doi: 10.1016/j.jmb.2012.01.024. Epub 2012 Feb 1. J Mol Biol. 2012. PMID: 22321796 Review.
Therapy of amyloid diseases.
Linke RP. Linke RP. Ren Fail. 1993;15(3):395-400. doi: 10.3109/08860229309054951. Ren Fail. 1993. PMID: 8516497 Review.
461 results